"""
Question: 1101 

Evidence: The cross-sectional study included people living with HIV on combined antiretroviral therapy and who had experienced virological failure during 2018-2019. All nucleotide sequences are available from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers POL (MW545333-MW545424) and ENV (MW582429-MW582506).

Rationale: The study describes newly collected clinical samples (2018–2019) that were sequenced and deposited in GenBank with specific accession numbers, indicating that it reports original, previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Sequencing of the protease/reverse transcriptase (PR/RT) and C2V3 of the viral envelope gp120 (Env) regions was analyzed to determine subtypes/variants of HIV-1, DRMs, and tropism. All nucleotide sequences are available from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers POL (MW545333-MW545424) and ENV (MW582429-MW582506).

Rationale: The paper explicitly states that HIV genomic regions (pol PR/RT and env C2V3) were sequenced and provides GenBank accession numbers, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: This cross-sectional study included 100 individuals with positive HIV-1 serology, who were older than 18 years of age, undergoing antiretroviral therapy for at least six months and presenting virologic failure (viral load ≥ 1000 copies/ml of plasma), receiving a medical request for HIV-1 genotyping. The amplified PCR products were purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, United Kingdom) following the manufacturer’s instructions. The products were subsequently subjected to sequencing using ABI BigDye Terminator v.3.1 Cycle Sequencing Ready (Applied Biosystems, United States).

Rationale: The methods and study design focus on sequencing clinical samples; there is no description of any in vitro passage experiments. Therefore, the paper does not report in vitro passage experiment results.

Answer: No
"""

"""
Question: 1104 

Evidence: Analysis of PR/RT resistance mutations was performed for each sequence on the Stanford HIV Drug Resistance Database website (http://hivdb.stanford.edu/). The susceptibility of each sequence to the ARV was also determined using the HIVdb Program from the Stanford HIV Drug Resistance Database. However, concerning the resistance level to the ARV only the high-level resistance was applied.

Rationale: The paper used genotypic interpretation (Stanford HIVdb) rather than laboratory phenotypic susceptibility testing; no in vitro susceptibility assays or IC values were reported.

Answer: No
"""

"""
Question: 2101 

Evidence: All nucleotide sequences are available from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers POL (MW545333-MW545424) and ENV (MW582429-MW582506).

Rationale: The paper clearly lists GenBank accession numbers for the sequenced HIV isolates.

Answer: Yes
"""

"""
Question: 2102 

Evidence: This cross-sectional study included 100 individuals with positive HIV-1 serology, who were older than 18 years of age, undergoing antiretroviral therapy for at least six months and presenting virologic failure (viral load ≥ 1000 copies/ml of plasma), receiving a medical request for HIV-1 genotyping. All nucleotide sequences are available from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers POL (MW545333-MW545424) and ENV (MW582429-MW582506).

Rationale: The sequences were derived from clinical patient samples (not laboratory strains), and accession numbers are provided for these clinical isolates.

Answer: Yes
"""

"""
Question: 2103 

Evidence: All nucleotide sequences are available from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers POL (MW545333-MW545424) and ENV (MW582429-MW582506).

Rationale: The accession number ranges are explicitly given in the Data Availability section.

Answer: POL: MW545333–MW545424; ENV: MW582429–MW582506
"""

"""
Question: 2202 

Evidence: Among the 92 studied individuals, DRMs were observed in 82 sequences (89%), from those 91.5% presented DRMs associated with NRTI (n = 75) and 84.1% with NNRTI (n = 69). The most frequently detected DRMs were M184I/V (68/82; 82.9%), K70E/R (16/82; 19.5%), and T215F/Y (17/82; 20.7%) to NRTI and K103N/S (51/82; 62.1%), P225H (15/82; 18.2%), and V106A/I/M (11/82; 13.4%) to NNRTI.

Rationale: The paper reports aggregate frequencies of mutations across samples rather than lists of mutations for each individual sequenced isolate, indicating no per-sample mutation lists are provided.

Answer: No
"""

"""
Question: 2301 

Evidence: This cross-sectional study included 100 individuals with positive HIV-1 serology. Sequencing of the protease/reverse transcriptase (PR/RT) and C2V3 of the viral envelope gp120 (Env) regions was analyzed to determine subtypes/variants of HIV-1, DRMs, and tropism.

Rationale: The study explicitly concerns HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Phylogenetic inference (PR/RT-Env) showed that most sequences were B subtype, followed by BF1 or BC mosaic genomes and few F1 and C sequences. Among the variants of subtype B at PR/RT, 84.3% were pandemic (BPAN), and 15.7% were Caribbean (BCAR).

Rationale: The paper identifies subtypes B, F1, C, and recombinants BF1 and BC, and further categorizes subtype B variants as BPAN and BCAR (plus BBR variant noted in env).

Answer: Subtypes B, F1, C; recombinants BF1 and BC; subtype B variants BPAN and BCAR (and BBR in env).
"""

"""
Question: 2303 

Evidence: Sequencing of the protease/reverse transcriptase (PR/RT) and C2V3 of the viral envelope gp120 (Env) regions was analyzed. The final pol (partial PR/RT) and env (partial gp120) alignments contained a 1260 nucleotide (nt) and a 397 nt fragment, respectively.

Rationale: The genes sequenced were pol (protease and reverse transcriptase regions) and env (C2V3 region of gp120).

Answer: pol (protease and reverse transcriptase) and env (C2V3 region of gp120)
"""

"""
Question: 2304 

Evidence: The final pol (partial PR/RT) ... alignments contained a 1260 nucleotide (nt) (positions 2254-3514 relative to the HXB2). Of the 100 individuals enrolled in the study, we were able to amplifiy 95% at the PR/RT region and to sequence 92% of them.

Rationale: The paper presents sequencing and analysis of the pol PR/RT region, confirming it reports results of HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: All subjects were treated at the Tropical Medicine Foundation-Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas state, Brazil. Thus, this study is aimed at investigating the genetic diversity of HIV-1 and DRM in Manaus.

Rationale: The sequences are from Manaus in the Amazonas state of Brazil.

Answer: Manaus, Amazonas state, Brazil (Northern Brazil)
"""

"""
Question: 2402 

Evidence: The cross-sectional study included people living with HIV on combined antiretroviral therapy and who had experienced virological failure during 2018-2019. All individuals were included in the study and had their samples collected between 2018 and 2019.

Rationale: The collection years are explicitly stated as 2018–2019.

Answer: 2018–2019
"""

"""
Question: 2502 

Evidence: The products were subsequently subjected to sequencing using ABI BigDye Terminator v.3.1 Cycle Sequencing Ready (Applied Biosystems, United States). The samples were sequenced in the ABI Prism 3130 automatic sequencer (Applied Biosystems).

Rationale: ABI BigDye and ABI 3130 indicate Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: The products were subsequently subjected to sequencing using ABI BigDye Terminator v.3.1 Cycle Sequencing Ready (Applied Biosystems, United States). The samples were sequenced in the ABI Prism 3130 automatic sequencer (Applied Biosystems).

Rationale: The methods describe Sanger sequencing; no NGS technology is mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: The amplified PCR products were purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, United Kingdom) following the manufacturer’s instructions. The products were subsequently subjected to sequencing using ABI BigDye Terminator v.3.1 Cycle Sequencing Ready.

Rationale: The workflow describes direct sequencing of purified PCR products without cloning, indicating samples were not cloned prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Extraction of genetic materials was performed using the QIAamp RNA mini kit ... followed by reverse transcription ... nested PCR ... The products were subsequently subjected to sequencing using ABI BigDye Terminator v.3.1 ... ABI Prism 3130.

Rationale: The study used bulk nested PCR and direct Sanger sequencing; there is no mention of single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: The amplified PCR products were purified ... The products were subsequently subjected to sequencing using ABI BigDye Terminator v.3.1 ... ABI Prism 3130. 

Rationale: The methods do not describe molecular cloning; they performed direct sequencing of PCR products.

Answer: No
"""

"""
Question: 2601 

Evidence: A sample of 4 ml of whole blood was collected by venous pulse, and the samples were processed for plasma separation and stored at -80°C until RNA extraction. Extraction of genetic materials was performed ... followed by reverse transcription of RNA to obtain cDNA.

Rationale: Sequencing was performed on RNA extracted from plasma, indicating plasma HIV sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: A sample of 4 ml of whole blood was collected ... processed for plasma separation and stored at -80°C until RNA extraction. 

Rationale: The paper specifies plasma-based RNA extraction and does not mention PBMC-derived sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Of the 100 individuals enrolled in the study, we were able to amplifiy 95% at the PR/RT region and to sequence 92% of them. A sample of 4 ml of whole blood was collected ... processed for plasma separation and stored at -80°C until RNA extraction.

Rationale: Sequencing was performed from plasma RNA, and 92% of the 100 individuals yielded sequences; thus, 92 plasma virus sequences were obtained.

Answer: 92
"""

"""
Question: 2604 

Evidence: A sample of 4 ml of whole blood was collected ... processed for plasma separation and stored at -80°C until RNA extraction. 

Rationale: Only plasma-based sequencing is described; there is no PBMC sequencing reported.

Answer: 0
"""

"""
Question: 2605 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure (viral load ≥ 1000 copies/ml of plasma). The cross-sectional study included people living with HIV ... who had experienced virological failure during 2018-2019.

Rationale: Virologic failure with detectable plasma viral loads indicates active HIV replication at the time of sampling.

Answer: Yes
"""

"""
Question: 2606 

Evidence: A sample of 4 ml of whole blood was collected ... processed for plasma separation and stored at -80°C until RNA extraction. 

Rationale: Sequencing was performed from plasma RNA, not from cellular proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: This cross-sectional study included 100 individuals with positive HIV-1 serology, who were older than 18 years of age. 

Rationale: All participants were adults; therefore, no infants or children were included.

Answer: No
"""

"""
Question: 2702 

Evidence: This cross-sectional study included 100 individuals ... receiving a medical request for HIV-1 genotyping following the guidelines of the Brazilian Ministry of Health at the time of the study. All subjects were treated at the Tropical Medicine Foundation-Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas state, Brazil.

Rationale: The study is observational and clinic-based; there is no explicit mention of clinical trial participation, so this cannot be determined from the text.

Answer: NA
"""

"""
Question: 2703 

Evidence: This cross-sectional study included 100 individuals ... receiving a medical request for HIV-1 genotyping ... All subjects were treated at the Tropical Medicine Foundation-Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas state, Brazil.

Rationale: The paper does not state that participants were in a clinical trial; thus, whether all were in a trial cannot be determined.

Answer: NA
"""

"""
Question: 3101 

Evidence: This cross-sectional study included 100 individuals with positive HIV-1 serology ... All individuals were included in the study and had their samples collected between 2018 and 2019.

Rationale: The paper states that samples were collected from all 100 individuals for genotyping.

Answer: 100
"""

"""
Question: 3102 

Evidence: Of the 100 individuals enrolled in the study, we were able to amplifiy 95% at the PR/RT region and to sequence 92% of them.

Rationale: Not all individuals yielded sequences; only 92% were successfully sequenced.

Answer: No
"""

"""
Question: 4101 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure (viral load ≥ 1000 copies/ml of plasma).

Rationale: All participants were ART-experienced; no ART-naive individuals were included.

Answer: No
"""

"""
Question: 4102 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure (viral load ≥ 1000 copies/ml of plasma).

Rationale: Inclusion criteria explicitly required prior antiretroviral therapy, indicating sequences are from ARV-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure. 

Rationale: Only ART-experienced individuals were included; there were no ART-naive participants.

Answer: No
"""

"""
Question: 4104 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure (viral load ≥ 1000 copies/ml of plasma).

Rationale: Since all participants were ART-experienced, the number of ART-naive individuals is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: The patients from this cohort presented a mean of six years (IQR 4-7) receiving cATR, 57.6% of them were receiving their first treatment, and 42.4% had already undergone treatment changes (TARV). All patients were taking NRTIs at the time the genotyping test was done, with 3TC being used by 92.6% ... and TDF by 84.1%....

Rationale: The paper provides summary statistics of ART histories and drug usage but does not give complete, detailed ART histories for each individual.

Answer: No
"""

"""
Question: 4201 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure. 

Rationale: Transmitted drug resistance pertains to ART-naive individuals; this study does not analyze ART-naive cases, so it does not report TDR prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: This cross-sectional study included 100 individuals ... undergoing antiretroviral therapy for at least six months and presenting virologic failure. 

Rationale: Pretreatment drug resistance refers to resistance prior to ART initiation; this cohort consists of ART-experienced individuals at failure, so pretreatment resistance prevalence is not reported.

Answer: No
"""

"""
Question: 4301 

Evidence: All patients were taking NRTIs at the time the genotyping test was done, with 3TC being used by 92.6% ... and TDF by 84.1%.... Concerning NNRTIs, all individuals had already used EFV.... Only half of the individuals had used PI (n = 46/82).

Rationale: The drug classes received include NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs
"""

"""
Question: 4302 

Evidence: Table 1 lists ARVs: 3TC, TDF, AZT, EFV, LPV, ATZ/r, DRV. Sequencing and resistance analysis were limited to PR/RT and env regions.

Rationale: No integrase inhibitors are mentioned among the drugs received or analyzed; thus, no information on individuals receiving INSTIs is reported.

Answer: No
"""

"""
Question: 4303 

Evidence: Only half of the individuals had used PI (n = 46/82), only 17% of individuals presented DRMs associated with protease inhibitors (n=14). ATZ/r was the most ARV used at the time of the genotyping test (23.1%, n = 19/82).

Rationale: The paper reports usage and resistance data for protease inhibitors.

Answer: Yes
"""

"""
Question: 4304 

Evidence: All patients were taking NRTIs ... Concerning NNRTIs, all individuals had already used EFV; however, only 63.4% were currently using this ARV at the collection time. Only half of the individuals had used PI (n = 46/82).

Rationale: Different individuals received different classes and drugs, indicating they did not all receive the same ART regimen.

Answer: No
"""

"""
Question: 4305 

Evidence: Sequencing and analysis targeted PR/RT (pol) and env; no integrase region was sequenced. Table 1 lists ARVs used and does not include integrase inhibitors.

Rationale: The paper does not state whether participants ever received INSTIs; therefore, INSTI-naive status cannot be determined.

Answer: NA
"""

"""
Question: 4403 

Evidence: The patients from this cohort presented a mean of six years (IQR 4-7) receiving cATR, 57.6% of them were receiving their first treatment, and 42.4% had already undergone treatment changes (TARV). Of the 100 individuals enrolled in the study, ... 92% [were] sequenced.

Rationale: “Treatment changes” indicate more than one regimen; applying 42.4% to the 92 sequenced individuals yields approximately 39 individuals (0.424 × 92 ≈ 39).

Answer: 39
"""

"""
Question: 4404 

Evidence: The patients from this cohort presented a mean of six years ... 57.6% ... first treatment, and 42.4% had already undergone treatment changes (TARV).

Rationale: The paper does not specify how many had more than two regimens; only that 42.4% had at least one change. The exact number with more than two regimens is not provided.

Answer: NA
"""

"""
Question: 4405 

Evidence: 57.6% of them were receiving their first treatment, and 42.4% had already undergone treatment changes (TARV).

Rationale: Because some individuals were on their first regimen while others had changed regimens, they did not all receive the same number of ART regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: 57.6% of them were receiving their first treatment, and 42.4% had already undergone treatment changes (TARV).

Rationale: Since 42.4% had changed treatment, not all individuals received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Table 1 lists ARVs used at any time and currently in use and includes 3TC, TDF, AZT, EFV, LPV, ATZ/r, and DRV. 

Rationale: Dolutegravir (an INSTI) is not listed among ARVs received, and the paper does not otherwise report dolutegravir use; the number cannot be determined from the text.

Answer: NA
"""

"""
Question: 4502 

Evidence: DRV 6/82 (7.3). DRV ... ARV current in use, (%) 4/82 (4.8).

Rationale: Table 1 indicates that 6 of 82 individuals (in the subset analyzed for ARV use/resistance) had received darunavir at any time.

Answer: 6
"""

"""
Question: 5101 

Evidence: Among the 92 studied individuals, DRMs were observed in 82 sequences (89%). 

Rationale: The paper states the number of individuals with at least one drug resistance mutation explicitly.

Answer: 82
"""

"""
Question: 5102 

Evidence: Sequencing of the protease/reverse transcriptase (PR/RT) and C2V3 of the viral envelope gp120 (Env) regions was analyzed. 

Rationale: The integrase gene was not sequenced or analyzed; therefore, INSTI-resistance mutations were not assessed or reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: However, only 6 from those 70 individuals that were taking TDF (8.5%) had high resistance level against TDF, despite its high use. TDF 70/82 (85.3) ARV used.

Rationale: The paper reports that 6 individuals had high-level resistance to TDF among those who had used TDF.

Answer: 6
"""

"""
Question: 5104 

Evidence: Sequencing of the protease/reverse transcriptase (PR/RT) and C2V3 of the viral envelope gp120 (Env) regions was analyzed. Analysis of PR/RT resistance mutations was performed ... using the Stanford HIV Drug Resistance Database.

Rationale: The study did not analyze the integrase region; hence, no INSTI-resistance mutations are reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: The susceptibility of each sequence to the ARV was also determined using the HIVdb Program from the Stanford HIV Drug Resistance Database. However, concerning the resistance level to the ARV only the high-level resistance was applied.

Rationale: The study used genotypic interpretation rather than phenotypic susceptibility testing; thus, no phenotypic method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: The susceptibility of each sequence to the ARV was also determined using the HIVdb Program from the Stanford HIV Drug Resistance Database. 

Rationale: No IC50 or IC90 values are reported; susceptibility was inferred genotypically.

Answer: No
"""

"""
Question: 6103 

Evidence: The susceptibility of each sequence to the ARV was also determined using the HIVdb Program ... only the high-level resistance was applied.

Rationale: No fold-change IC50 values are provided; only categorical genotypic resistance levels are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: Analysis of PR/RT resistance mutations was performed ... Stanford HIV Drug Resistance Database ... The susceptibility ... was also determined using the HIVdb Program.

Rationale: No phenotypic assay is used; the approach is purely genotypic.

Answer: NA
"""

"""
Question: 6105 

Evidence: The paper describes sequencing, resistance mutation analysis, and genotypic susceptibility interpretation. 

Rationale: There is no mention of replication capacity assays or results.

Answer: No
"""

"""
Question: 6106 

Evidence: The susceptibility of each sequence to the ARV was also determined using the HIVdb Program ... only the high-level resistance was applied.

Rationale: No phenotypic susceptibility testing was performed; hence no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: This cross-sectional study included 100 individuals ... presenting virologic failure ... receiving a medical request for HIV-1 genotyping. The amplified PCR products were purified ... subsequently subjected to sequencing ...

Rationale: The sequences are derived from patient viruses; the paper does not describe any site-directed mutagenesis constructs.

Answer: No
"""

"""
Question: 7102 

Evidence: This cross-sectional study included 100 individuals ... presenting virologic failure ... receiving a medical request for HIV-1 genotyping. The amplified PCR products were purified ... subsequently subjected to sequencing ...

Rationale: The study sequenced clinical samples and does not report any in vitro passage of virus.

Answer: No
"""